[1]
|
Thomsen, H.S. and Webb, J. (2012) The Lalli and Weber effects and the incidence of acute non-renal adverse reactions to contrast media. Acta Radiologica, 53, 953-954.
doi:10.1258/ar.2012.12a006
|
[2]
|
Lalli, A.F. (1980) Contrast media reactions: Data analysis and hypothesis. Radiology, 134, 1-12.
|
[3]
|
Weber, J.C.P. (1984) Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. In: Rainsford, K.D. and Velo, G.D., Eds., Side-effects of anti-inflammatory drugs, advances in inflammation research. Raven Press, New York, 1-7.
|
[4]
|
Schild, H.H., Kuhl, C.K., Hübner-Steiner, U., Bohm, I. and Speck, U. (2006) Adverse events after unenhanced and monomeric and dimeric contrast-enhanced CT: A prospective randomized controlled trial. Radiology, 240, 56-64. doi:10.1148/radiol.2393050560
|
[5]
|
Dillman, J.R., Ellis, J.H., Cohan, R.H., Strouse, P.J. and Jan, S.C. (2007) Frequency and severity of acute allergic-like reactions to gadolinium-containing IV contrast media in children and adults. AJR American Journal of Roentgenology, 189, 1533-1538. doi:10.2214/AJR.07.2554
|
[6]
|
Murphy, K.J., Brunberg, J.A. and Cohan, R.H. (1996) Adverse reactions to gadolinium contrast media: A review of 36 cases. AJR American Journal of Roentgenology, 167, 847-849. doi:10.2214/ajr.167.4.8819369
|
[7]
|
Knopp, M.V., Balzer, T., Esser, M., Kashanian, F.K., Paul, P. and Niendorf, H.P. (2006) Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentate dimeglumine as a magnetic resonance contrast media after 45 million administrations and 15 years of clinical use. Investigative Radiology, 41, 491-499.
doi:10.1097/01.rli.0000209657.16115.42
|
[8]
|
Morcos, S.K. and Thomsen, H.S. (2001) Adverse reactions to iodinated contrast media. European Radiology, 11, 1267-1275. doi:10.1007/s003300000778
|
[9]
|
Thomsen, H.S. (1997) Frequency of acute adverse events to a non-ionic low-osmolar contrast medium: The effect of verbal interview. Pharmacology & Toxicology, 80, 108-110. doi:10.1111/j.1600-0773.1997.tb00292.x
|
[10]
|
Niendorf, H.P., Dinger, J.C., Haustein, J., Cornelius, I., Alhassan, A. and Clauss, W. (1991) Tolerance data of Gd-DTPA: A review. European Journal of Radiology, 13, 15-20. doi:10.1016/0720-048X(91)90049-2
|
[11]
|
Nelson, K.L., Gifford, L.M., Lauber-Huber, C., Gross, C.A. and Lasser, T.A. (1995) Clinical safety of gadopentetate dimeglumine. Radiology, 196, 439-443.
|
[12]
|
Hunt, C.H., Hartman, R.P. and Hesley, G.K. (2009) Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: Retrospective review of 456,930 doses. AJR American Journal of Roentgenology, 193, 1124-1127. doi:10.2214/AJR.09.2520
|
[13]
|
Goldstein, H.A., Kashanian, F.K., Blumettei, R.F., Holyoak, W.L., Hugo, F.P. and Blumenfield, D.M. (1990) Safety assessment of gadopentetate dimeglumine in US clinical trials. Radiology, 174, 17-23.
|
[14]
|
Shellock, F.G., Morisoli, S.M. and Ziarati, M. (1994) Measurement of acoustic noise during MR imaging: Evaluation of six “Worst-Case” pulse sequences. Radiology, 191, 91-93.
|
[15]
|
Forsting, M. and Palkowitsch, P. (2010) Prevalence of Acute adverse events to gadobutrol—A highly concentrated macrocyclic gadolinium chelate: Review of 14,299 patients from observational trials. European Journal of Radiology, 74, e186-e192.
doi:10.1016/j.ejrad.2009.06.005
|
[16]
|
Bruder, O., Schneider, S., Nothnagel, D., Pilz, G., Lombardi, M., Sinha, A., Wagner, A., Dill, T., Frank, H, van Rossum, A., Schwitter, J., Nagel, E., Senges, J., Sabin, G., Sechtem, U. and Mahrholdt, H. (2011) Acute adverse events to gadolinium-based contrast agents in CMR: multicenter experience with 17,767 patients from the Euro CMR Registry. JACC Cardiovasc Imaging, 4, 1171-1176.
doi:10.1016/j.jcmg.2011.06.019
|
[17]
|
Abujudeh, H.H., Kosaraju, V.K. and Kaewlai, R. (2010) Acute adverse events to gadopentetate dimeglumine and gadobenate dimeglumine: Experience with 32,659 injections. AJR American Journal of Roentgenology, 194, 430-434. doi:10.2214/AJR.09.3099
|
[18]
|
Li, A., Wong, C.S., Wong, M.K., Lee, C.M. and Au Yeung, M.C. (2006) Acute adverse events to magnetic resonance contrast media: Gadolinium chelates. British Journal of Radiology, 79, 368-371. doi:10.1259/bjr/88469693
|
[19]
|
Herborn, C.U., Honold, E., Wolf, M., Kemper, J., Kinner, S., Adam, G. and Barkhausen, J. (2007) Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Investigative Radiology, 42, 58-62. doi:10.1097/01.rli.0000248893.01067.e5
|
[20]
|
Ishiguchi, T. and Takahashi, S. (2010) Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: Results of a post-marketing surveillance study in Japan. Drugs R D, 10, 133-145.
doi:10.2165/11539140-000000000-00000
|
[21]
|
Dooley, M. and Jarvis, B. (2000) Iomeprol: A review of its use as a contrast medium. Drugs, 59, 1169-1186.
doi:10.2165/00003495-200059050-00013
|
[22]
|
Davenport, M.S., Dillman, J.R., Cohan, R.H., Hussain, H.K., Khalatbari, S., McHugh, J.B. and Ellis, J.H. (2013) Effect of abrupt substitution of gadobenate dimeglumine for gadopentetate dimeglumine on rate of allergic-like reactions. Radiology, 266, 773-782.
doi:10.1148/radiol.12120253
|
[23]
|
Brugières, P., Gaston, A., Degryse, H.R., Parizel, P.M., de Schepper, A.M., Berry, I., Manelfe, C., Le Bras, F., Marsault, C., Wichmann, W. and Valavanis, A. (1994) Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA). Neuroradiology, 36, 27-30. doi:10.1007/BF00599189
|